MX2016001541A - Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. - Google Patents
Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos.Info
- Publication number
- MX2016001541A MX2016001541A MX2016001541A MX2016001541A MX2016001541A MX 2016001541 A MX2016001541 A MX 2016001541A MX 2016001541 A MX2016001541 A MX 2016001541A MX 2016001541 A MX2016001541 A MX 2016001541A MX 2016001541 A MX2016001541 A MX 2016001541A
- Authority
- MX
- Mexico
- Prior art keywords
- muc1
- treatment
- solid tumors
- maytansinoid immunoconjugate
- immunoconjugate antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306119 | 2013-08-02 | ||
| PCT/EP2014/066345 WO2015014879A1 (en) | 2013-08-02 | 2014-07-30 | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001541A true MX2016001541A (es) | 2016-08-18 |
Family
ID=49036539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001541A MX2016001541A (es) | 2013-08-02 | 2014-07-30 | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347856A1 (enExample) |
| EP (1) | EP3027218A1 (enExample) |
| JP (1) | JP2016525560A (enExample) |
| KR (1) | KR20160035600A (enExample) |
| CN (1) | CN105592861A (enExample) |
| AU (1) | AU2014298514A1 (enExample) |
| CA (1) | CA2919932A1 (enExample) |
| EA (1) | EA201690321A1 (enExample) |
| IL (1) | IL243843A0 (enExample) |
| MX (1) | MX2016001541A (enExample) |
| TW (1) | TW201605479A (enExample) |
| WO (1) | WO2015014879A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109147874A (zh) * | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| GB201506388D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| CN105997942B (zh) * | 2016-06-24 | 2019-01-29 | 浙江大学 | 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用 |
| EP3570881A4 (en) * | 2017-01-18 | 2020-08-19 | Nanocruise Pharmaceutical Ltd. | MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE |
| EP3665161B1 (en) * | 2017-08-09 | 2023-09-27 | Helmholtz-Zentrum für Infektionsforschung GmbH | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| CN113260383A (zh) * | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291898A (zh) * | 1998-02-25 | 2001-04-18 | 若素制药株式会社 | 用于角膜上皮疾病的药物 |
| AU2004258955C1 (en) * | 2003-07-21 | 2012-07-26 | Immunogen, Inc. | A CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| EA020130B9 (ru) * | 2005-08-22 | 2014-10-30 | Иммьюноджен, Инк. | Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| CN102596922A (zh) * | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
-
2014
- 2014-07-30 WO PCT/EP2014/066345 patent/WO2015014879A1/en not_active Ceased
- 2014-07-30 AU AU2014298514A patent/AU2014298514A1/en not_active Withdrawn
- 2014-07-30 MX MX2016001541A patent/MX2016001541A/es unknown
- 2014-07-30 EA EA201690321A patent/EA201690321A1/ru unknown
- 2014-07-30 CN CN201480054398.5A patent/CN105592861A/zh active Pending
- 2014-07-30 CA CA2919932A patent/CA2919932A1/en not_active Withdrawn
- 2014-07-30 JP JP2016530509A patent/JP2016525560A/ja not_active Abandoned
- 2014-07-30 KR KR1020167004778A patent/KR20160035600A/ko not_active Withdrawn
- 2014-07-30 EP EP14747592.5A patent/EP3027218A1/en active Pending
- 2014-07-30 US US14/909,671 patent/US20160347856A1/en not_active Abandoned
- 2014-08-01 TW TW103126492A patent/TW201605479A/zh unknown
-
2016
- 2016-01-31 IL IL243843A patent/IL243843A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015014879A1 (en) | 2015-02-05 |
| AU2014298514A1 (en) | 2016-03-10 |
| WO2015014879A9 (en) | 2015-11-19 |
| JP2016525560A (ja) | 2016-08-25 |
| IL243843A0 (en) | 2016-04-21 |
| CN105592861A (zh) | 2016-05-18 |
| CA2919932A1 (en) | 2015-02-05 |
| KR20160035600A (ko) | 2016-03-31 |
| EA201690321A1 (ru) | 2016-12-30 |
| EP3027218A1 (en) | 2016-06-08 |
| TW201605479A (zh) | 2016-02-16 |
| US20160347856A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| MX2023003806A (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso. | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| MX381017B (es) | Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| UA115517C2 (uk) | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b | |
| MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| IN2015MN00001A (enExample) | ||
| PH12020551715A1 (en) | Methods of treating cancer | |
| BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
| SG11202011243XA (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
| PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
| SG179192A1 (en) | Methods for treating brain tumors | |
| NZ625758A (en) | Method for treating breast cancer | |
| EA201200190A1 (ru) | Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы |